Capricor
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
CAPR Key Statistics
Stock Snapshot
As of today, Capricor(CAPR) shares are valued at $30.39. The company's market cap stands at 1.66B, with a P/E ratio of -13.52.
As of 2026-03-14, Capricor(CAPR) stock has fluctuated between $29.41 and $33.00. The current price stands at $30.39, placing the stock +3.3% above today's low and -7.9% off the high.
Capricor(CAPR) shares are trading with a volume of 2.61M, against a daily average of 1.85M.
In the last year, Capricor(CAPR) shares hit a 52-week high of $40.37 and a 52-week low of $4.30.
In the last year, Capricor(CAPR) shares hit a 52-week high of $40.37 and a 52-week low of $4.30.
CAPR News
Capricor Therapeutics, Inc. ((CAPR)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium Unlock hedge fun...
Piper Sandler raised the firm’s price target on Capricor Therapeutics (CAPR) to $58 from $45 and keeps an Overweight rating on the shares. The firm notes Capric...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Analyst ratings
100%
of 9 ratingsMore CAPR News
Earnings Call Insights Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone Mar. 12, 2026 8:02 PM ET Capr...
Wondering whether Capricor Therapeutics at around US$33.57 is still offering value or has already priced in the story? This article will walk you through what t...
Capricor Therapeutics (CAPR) announced additional analyses and new functional outcomes data from the Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne mus...
Capricor Therapeutics announced that the FDA has lifted its prior Complete Response Letter and resumed review of the Biologics License Application for Deramioce...
Capricor Therapeutics ( (CAPR) ) has shared an update. On March 10, 2026, Capricor Therapeutics said the U.S. Food and Drug Administration lifted a prior Compl...
Capricor Therapeutics (CAPR) announced that the U.S. Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed review o...
The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center for Biologics Evaluation and Resea...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.